Nerviano Medical Sciences

What Nerviano Medical Sciences does

Nerviano Medical Sciences S.r.l. (NMS) is a privately held, clinical-stage oncology biopharmaceutical company headquartered in Nerviano (Milan), Italy, with operational offices in Corsico, Italy; Cambridge, Massachusetts; and Shanghai, China. The company was carved out of Pfizer's Nerviano research site in 2004 and is 100% owned by PAG via Luxembourg Investment Company 240 Sarl. NMS employs 101-250 staff and is led by CEO Hugues Dolgos, with the discovery and translational organization anchored by CSO Alessia Montagnoli.

The company operates two core technology platforms: (1) a small-molecule kinase inhibitor discovery platform built around a proprietary Kinase Targeted Library of ~100,000 molecules, a Kinase Selectivity Screening panel of 100+ automated biochemical kinase assays, in-house enzyme protein production, and an NAD+ binding family platform targeting ~17 PARP enzymes; and (2) a proprietary ADC payload-linker platform with three differentiated payload families (duocarmycins, next-generation anthracyclines, and targeted payloads) and HydroShield hydrophilic linker technology, supported by more than 1,000 granted patents/applications and 310+ publications since 2004. The pipeline includes two marketed assets (encorafenib and entrectinib) and clinical-stage programs itareparib (PARP1, Phase 2 in glioblastoma, with new Phase 1 combinations in SCLC and BRCA-wild-type ovarian cancer initiated in 2025), atamparib (PARP7, acquired from Ribon Therapeutics in November 2024), NMS-812 (PERK/GCN2, Phase 1 in AML), and preclinical ADC candidates against HER3 and Nectin-4. NMS-153 (MPS1) was discontinued in March 2026 and the onvansertib license to Cardiff Oncology was terminated in May 2026.

NMS operates a B2B out-licensing and royalty model. It discovers and advances molecules through Phase I/II, then licenses enabling IP to large pharmaceutical partners for global commercialization (Novartis for encorafenib, Roche for entrectinib) and to biotech partners for co-development (Italfarmaco for the SSTR2 PDC ITF3912). NMS monetizes royalty streams on approved drugs through specialty-finance transactions (Blue Owl Capital for encorafenib in September 2024; NovaQuest for entrectinib in March 2025). In July 2025, the company announced a strategic portfolio focus on PARP1, PARP7, MPS1, and the ADC platform, with the wind-down of laboratory operations at the Nerviano BioN campus and relocation of office-based headquarters to Corsico. NMS does not sell products directly to patients or providers; end-product pricing and distribution are set by partner companies.

Name

Nerviano Medical Sciences

Legal name

Nerviano Medical Sciences S.r.l.

Website

https://nervianoms.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

Nerviano Medical Sciences is a privately held, clinical-stage oncology biopharmaceutical company that discovers small-molecule kinase and PARP inhibitors and next-generation ADC payload-linker technologies, then out-licenses IP to large pharma partners such as Novartis and Roche for commercialization, with royalty streams partially monetized through specialty-finance deals.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Oncology drug discovery
• Kinase inhibitor platform
• ADC payload-linker technology
• PARP inhibitor pipeline
• Biopharmaceutical out-licensing

Headquarters

HQ city

Nerviano

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Out-licensing of drug IP: NMS discovers and develops molecules through early clinical stages, then out-licenses enabling IP to larger pharmaceutical companies for global commercialization. Examples: encorafenib IP licensed to Novartis; entrectinib licensed to Ignyta (acquired by Roche).
2. Royalty agreements on approved drugs: NMS retains royalty interests on approved drugs commercialized by partners. Encorafenib (BRAFTOVI) generates royalties via agreement with Blue Owl Capital (September 2024). Entrectinib (ROZLYTREK) generates royalties via agreement with NovaQuest Capital Management (March 2025).
3. ADC and payload-linker technology licensing: NMS licenses out its proprietary payload-linker technologies and IND-ready ADCs to pharma/biotech partners for co-development and clinical advancement, generating upfront, milestone, and royalty payments.
4. Licensing dispute / termination: NMS terminated the license agreement for onvansertib with Cardiff Oncology on May 27, 2026, citing material breach including failure to correct patent inventorship and lack of commercially reasonable development efforts.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Nerviano Medical Sciences is a clinical-stage oncology biopharmaceutical company that discovers and develops small molecule kinase inhibitors, PARP inhibitors, and next-generation antibody-drug conjugate (ADC) payload-linker technologies. It advances investigational therapies through Phase I/II clinical trials in-house, then out-licenses IP and development-stage assets to large pharmaceutical partners (Novartis, Roche) for global commercialization, while monetizing royalty streams and licensing its proprietary ADC technology to biotech partners for co-development.

Product overview

Nerviano Medical Sciences (NMS) is a clinical-stage oncology-focused biopharmaceutical company with a diversified pipeline spanning small molecule kinase inhibitors, PARP inhibitors, and a proprietary ADC platform. The company operates two core drug discovery platforms: a Kinase Platform featuring ~100,000 proprietary compounds and over 100 automated kinase assays, and an NAD+ Binding Platform targeting the PARP enzyme family (~17 enzymes). The marketed drugs Encorafenib (BRAFTOVI) and Entrectinib (ROZLYTREK) were out-licensed to Novartis and Roche respectively. The clinical-stage pipeline includes Itareparib (NMS-293, PARP1) in Phase 2 for glioblastoma, Atamparib (PARP7) in Phase 1/2, and NMS-812 (PERK/GCN2) in Phase 1 for AML. The proprietary ADC Platform features novel duocarmycin and next-generation anthracycline payloads with HydroShield linker technology. The company has affiliates in Italy (Nerviano/Corsico), USA (Boston), and China (Shanghai).

Differentiator

Problem solved

Functional benefit

Products and services

• Encorafenib (BRAFTOVI) Small molecule BRAF kinase inhibitor for treatment of BRAF V600E/K-mutated melanoma (combined with binimetinib as BRAFTOVI), BRAF V600E-mutated metastatic colorectal cancer (combined with cetuximab), and BRAF V600E-mutated NSCLC. NMS licensed enabling IP rights to Novartis; royalty agreement with Blue Owl Capital signed September 2024.
• Entrectinib (ROZLYTREK) Selective inhibitor of TRK A/B/C, ROS1, and ALK tyrosine kinases for NTRK fusion-positive and ROS1-positive metastatic NSCLC including brain metastases. Invented by NMS, licensed to Ignyta (now Roche), marketed as ROZLYTREK. Royalty agreement with NovaQuest Capital Management signed March 2025.
• Itareparib (NMS-293) Third-generation, non-trapping, PARP1-selective inhibitor with high brain penetrance designed for combination with DNA-damaging agents. Currently in Phase 2 for relapsed glioblastoma (IDH wild type) with temozolomide, and Phase 1 for BRCA wild-type ovarian cancer and small cell lung cancer.
• Atamparib (PARP7) First-in-class, orally bioavailable PARP7-selective inhibitor acquired from Ribon Therapeutics in November 2024. Demonstrates favorable safety profile with early signs of efficacy in Phase I/II studies. Phase Ib/II trial in NSCLC adenocarcinoma initiated in China February 2026.
• NMS-812 (PERK/GCN2) Novel, orally bioavailable dual inhibitor of PERK and GCN2, key effectors of the Integrated Stress Response pathway. First-in-human study showed excellent PK profile. In clinical development for AML with potential in ovarian cancer and multiple myeloma.
• HER3 Novel Duocarmycin ADC ADC candidate using novel duocarmycin payload for HER3-expressing tumors including breast, colorectal, and NSCLC. Targets therapy-resistant tumors progressing on Topo I-based standard-of-care treatments.
• Nectin-4 Next-gen Anthracycline ADC ADC targeting Nectin-4 for epithelial tumors including esophageal, head & neck, TNBC, and urothelial cancers. Leverages next-generation anthracycline payload engineered for improved durability and safety.
• Peptide Drug Conjugates (PDCs) Non-exclusive partnered PDCs integrating optimized drug-linker chemistry with peptide targeting for enhanced tumor penetration and receptor-mediated binding. Partner ITF3912 targeting SSTR2 in neuroendocrine tumors progressing through IND-enabling studies.

Quantifiable outcome

• Encorafenib approved by FDA in 2 independent indications (BRAF-mutated melanoma combo, BRAF-mutated CRC combo) plus NSCLC; Entrectinib approved in 2 independent indications (NTRK fusion-positive, ROS1-positive NSCLC)
• +3 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• Roche AcceleratorcoreStrategic or Co-development Partner · 1 October 2025Nerviano Medical Sciences (Shanghai) Co., Ltd. officially joined the Roche Accelerator in October 2025. Roche Accelerator is Roche's first in-house accelerator globally, representing Roche's long-term commitment to Shanghai and China. The accelerator aims to catalyze and empower scientists and entrepreneurs to accelerate breakthrough innovation into next-generation therapeutics. NMS China leverages this partnership to advance its clinical pipeline and ADC portfolio in the Chinese market.
• Ignyta (acquired by Roche)coreOEM/ Whitelabel/ Licensing PartnerEntrectinib was invented by NMS and developed through Phase I, then licensed to Ignyta (San Diego, USA). Ignyta was subsequently acquired by Roche. Entrectinib is commercialized by Roche under the brand name ROZLYTREK for NTRK fusion-positive and ROS1-positive metastatic NSCLC. In March 2025, NMS signed a royalty agreement with NovaQuest Capital Management to monetize the entrectinib royalty stream.
• NovartiscoreOEM/ Whitelabel/ Licensing PartnerEncorafenib enabling IP was licensed to Novartis. BRAFTOVI (encorafenib) is approved in combination with binimetinib for BRAF V600E/K-mutated melanoma, in combination with cetuximab for metastatic CRC with BRAF V600E mutation, and in combination with MEKTOVI for metastatic NSCLC with BRAF V600E mutation. In September 2024, NMS signed a royalty agreement with Blue Owl Capital.
• Italfarmaco S.p.A.coreStrategic or Co-development PartnerItalfarmaco licensed NMS's proprietary duocarmycin payload-linker technology for development of ITF3912, a novel peptide-drug conjugate (PDC) targeting somatostatin receptor 2 (SSTR2) for neuroendocrine tumors and a subset of small cell lung cancers. At AACR 2026, preclinical data for ITF3912 was presented, showing high affinity, receptor-mediated internalization, DNA damage, and tumor cell death. IND-enabling studies are ongoing.
• Ribon TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerAtamparib (PARP7 inhibitor) was originally developed by Ribon Therapeutics and acquired by NMS in November 2024. This acquisition expanded NMS's diversified oncology portfolio with a novel first-in-class small molecule targeting PARP7, an enzyme upregulated in response to cellular stress and promoting cancer cell survival.

Scale indicators5 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Exelixis: Exelixis is a clinical-and-commercial oncology biopharma that discovers and develops small-molecule kinase inhibitors (e.g., cabozantinib). Like NMS, it pairs a kinase discovery engine with out-licensing/royalty economics, validating the model of privately originated kinase assets reaching global commercialization through partners.
• ADC Therapeutics: ADC Therapeutics is a commercial-stage biotech built around proprietary antibody-drug conjugate payloads and linkers. NMS's payload-linker platform with duocarmycin and next-gen anthracycline payloads targets the same ADC opportunity, making ADC Therapeutics the closest direct comparable in ADC-centric oncology drug development.
• Blueprint Medicines: Blueprint Medicines is a precision oncology company developing kinase-targeting small molecules for defined genetic patient populations. NMS's BRAF and TRK/ROS1 inhibitor portfolio and its focus on well-characterized kinase targets follow a similar biomarker-driven development paradigm.
• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide-based oncology conjugates — analogous to NMS's PDC and ADC work using duocarmycin payload-linker chemistry. Lisa Mahnke (NMS CMO) previously led clinical development at Bicycle, evidencing deep operational overlap in oncology bioconjugate R&D.
• Debiopharm: Debiopharm is a Swiss privately-held biopharma that discovers and develops oncology small molecules and out-licenses them globally. Its asset-discovery-plus-licensing model and European base closely parallel NMS's strategy of originating molecules in Italy and monetizing them through partnerships with large pharma.
• Syros Pharmaceuticals: Syros is a clinical-stage oncology biopharma focused on small-molecule therapeutics for defined patient subsets. NMS CMO Lisa Mahnke previously led clinical development at Syros, and the companies share a clinical-stage, biomarker-driven kinase/small-molecule oncology orientation.
• Puma Biotechnology: Puma Biotechnology is a clinical-to-commercial oncology biopharma with an out-licensed HER2-targeted small-molecule franchise. Its strategy of combining in-house discovery with partner-led commercialization mirrors NMS's reliance on Novartis/Roche for BRAFTOVI and ROZLYTREK while internalizing discovery.

Broad incumbents

• BridgeBio Oncology: BridgeBio has built a broad precision-oncology pipeline including kinase- and ADC-adjacent programs (BridgeBio Oncology Therapeutics), giving it a wider portfolio spanning multiple targets. Comparable as a broader oncology R&D operation rather than a focused kinase/ADC platform specialist.
• Servier (Institut de Recherche Servier): Servier is a global privately-held pharmaceutical company with a major oncology franchise and large in-house R&D. Multiple NMS senior leaders (CEO Hugues Dolgos, CMO Lisa Mahnke) previously held senior oncology roles at Servier, evidencing deep operational overlap in kinase-inhibitor and ADC oncology development.

Emerging players

• C4 Therapeutics: C4 Therapeutics is a clinical-stage oncology company developing targeted protein degraders with kinase-targeting applications. It overlaps with NMS in targeting well-characterized oncology kinases via new chemical modalities but uses a degrader rather than inhibitor approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks14 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nerviano-medical-sciences-s.r.l.
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nerviano Medical Sciences